Literature DB >> 19945130

Gene-expression phenotypes for vascular invasiveness of hepatocellular carcinomas.

Shinji Tanaka1, Kaoru Mogushi, Mahmut Yasen, Norio Noguchi, Atsushi Kudo, Noriaki Nakamura, Koji Ito, Yoshio Miki, Johji Inazawa, Hiroshi Tanaka, Shigeki Arii.   

Abstract

BACKGROUND: Gross vascular invasion is a well-established prognostic indicator in hepatocellular carcinoma (HCC), but the biological significance of microscopic invasion remains unclear.
METHODS: Curatively resected primary HCCs were classified retrospectively into 3 groups: HCCs without vascular invasion (V0), HCCs with microvascular invasion (V1), and HCCs with macrovascular invasion (V2). Microarray profiling of patients with V0, V1, and V2 using Jonckheere-Terpstra (JT) tests and Wilcoxon rank sum tests was performed.
RESULTS: Distinct patterns of gene expression were demonstrated between V0 and V2 groups; less (L) and highly (H) invasive phenotypes, respectively. It is noteworthy that 2 dendrograms by the hierarchical clustering provided exactly the same assignment results for V1 cases that were thus separated into L and H gene-expression phenotypes. Marked differences were found in overall (P < .001) and tumor-free survival (P < .001) between L and H gene-expression phenotypes. Multivariate analyses indicated that the phenotypes of the patterns of gene expression, rather than the clinicopathologic markers of vascular invasion, were independent predictors of tumor recurrence (P = .031). Using the gene-expression patterns identified by both JT and Wilcoxon rank sum test analyses, other V1 cases validated these differences in tumor-free survivals between gene-expression phenotypes within the group (P = .039).
CONCLUSION: Gene profiling suggested that microvascular invasiveness consisted of a classable mixture of 2 distinct phenotypes. Thus, gene-array analyses may have clinical benefit, because they may in fact be more predictive than other clinical factors. Copyright 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19945130     DOI: 10.1016/j.surg.2009.09.037

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

Review 1.  Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2010-05-27       Impact factor: 3.402

2.  Preoperative Prediction of Microvascular Invasion Risk Grades in Hepatocellular Carcinoma Based on Tumor and Peritumor Dual-Region Radiomics Signatures.

Authors:  Fang Hu; Yuhan Zhang; Man Li; Chen Liu; Handan Zhang; Xiaoming Li; Sanyuan Liu; Xiaofei Hu; Jian Wang
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

3.  Microscopic vascular invasion by hepatocellular carcinoma in liver transplant patients.

Authors:  Brian I Carr; Volkan Ince; Harika Gozukara Bag; Veysel Ersan; Sertac Usta; Sezai Yilmaz
Journal:  Clin Pract (Lond)       Date:  2020

4.  Self-Organizing Feature Maps Identify Proteins Critical to Learning in a Mouse Model of Down Syndrome.

Authors:  Clara Higuera; Katheleen J Gardiner; Krzysztof J Cios
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

5.  Prognostic value of a novel risk classification of microvascular invasion in patients with hepatocellular carcinoma after resection.

Authors:  Hui Zhao; Chuang Chen; Xu Fu; Xiaopeng Yan; Wenjun Jia; Liang Mao; Huihan Jin; Yudong Qiu
Journal:  Oncotarget       Date:  2017-01-17

6.  Prediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombin.

Authors:  Tomoharu Kurokawa; Shintaro Yamazaki; Yusuke Mitsuka; Masamichi Moriguchi; Masahiko Sugitani; Tadatoshi Takayama
Journal:  Br J Cancer       Date:  2015-12-17       Impact factor: 7.640

7.  Next-generation des-r-carboxy prothrombin for immunohistochemical assessment of vascular invasion by hepatocellular carcinoma.

Authors:  Shintaro Yamazaki; Tadatoshi Takayama; Tomoharu Kurokawa; Naoaki Shimamoto; Yusuke Mitsuka; Nao Yoshida; Tokio Higaki; Masahiko Sugitani
Journal:  BMC Surg       Date:  2020-09-14       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.